[1] Siegel RL,Miller KD,Jemal A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020,70:7-30. [2] Motzer RJ,Jonasch E,Agarwal N,et al. Kidney cancer,Version 2.2017,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017,15:804-834. [3] Motzer RJ,Bukowski RM,Figlin RA,et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma[J]. Cancer, 2008,113:1552-1558. [4] Janzen NK,Kim HL,Figlin RA,et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease[J]. Urol Clin North Am, 2003,30:843-852. [5] Hsieh JJ,Purdue MP,Signoretti S,et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017,3:17009. doi: 10.1038/nrdp.2017.9. [6] Serra S,Chetty R. Rnf43[J]. J Clin Pathol, 2018,71:1-6. [7] Jiang X,Hao HX,Growney JD,et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2013,110:12649-12654. [8] Tsukiyama T,Zou J,Kim J,et al. A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis[J]. Nat Commun,2020,11:4586. doi: 10.1038/s41467-020-18257-3. [9] Neumeyer V,Grandl M,Dietl A,et al. Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells[J]. Carcinogenesis, 2019,40:551-559. [10] Xing C,Zhou W,Ding S,et al. Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma[J]. Mol Cancer Ther, 2013,12:94-103. [11] Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68:394-424. |